| This promotional content is organised and funded by Pfizer Ltd on behalf of the BMS-Pfizer Alliance and is intended for UK Healthcare Professionals only |
Click here for Eliquis® (apixaban) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Eliquis (apixaban)
Eliquis (apixaban) is an oral, direct factor Xa inhibitor indicated for prevention of stroke / systemic embolism in adult patients with NVAF, with one or more risk factors (such as prior stroke or transient ischaemic attack, age ≥ 75 years, hypertension, diabetes mellitus, symptomatic heart failure [NYHA Class ≥ II]), treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.1
Masterclass TV
Visit Masterclass TV to watch on-demand content, discussing patient case studies, specifically designed to educate, motivate and inspire clinical excellence in the management of anticoagulation.
Horizon TV
Tune in to Horizon TV to watch LIVE clinical webinars, discussing challenging patient case studies, all designed for consolidating best practice for healthcare professionals.
Patient Information Booklets
Access materials to support your Eliquis patients for:
Treatment or prevention of DVT/PE
Switching from warfarin to Eliquis for stroke prevention in NVAF
Stroke prevention in NVAF
Please note that these resources are for healthcare professionals to download only for patients who have been prescribed Eliquis.
Video resources
NVAF video resources
Find out more about the use of Eliquis in NVAF
DVT/PE video resources
Find out more about the use of Eliquis in DVT/PE
Explore more
Explore data in NVAF
Switching to and from Eliquis
Explore data in DVT / PE
DVT = Deep Vein Thrombosis
NVAF = Non-Valvular Atrial Fibrillation
PE = Pulmonary Embolism
Reference:
1. Eliquis (apixaban) Summary of Product Characteristics available www.medicines.org.uk.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or
0800 731 1736 (UK).
PP-ELI-GBR-9785 Oct 2021
You can view the Pharmacy in Practice privacy policy here.